Results 41 to 50 of about 289,605 (341)

FA2H Exhibits Tumor Suppressive Roles on Breast Cancers via Cancer Stemness Control

Frontiers in Oncology, 2019
Background: Triple negative breast cancers are aggressive, enriched with cancer stem cells, and lack effective targeted therapies with little side effects.Methods: We isolated cancer stem cells from two triple negative breast cancer cell lines via cell ...
Xiaofeng Dai, Shuo Zhang, Hongye Cheng, Dongyan Cai, Dongyan Cai, Xiao Chen, Zhaohui Huang, Zhaohui Huang   +7 more
doaj   +1 more source

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

PLoS ONE, 2016
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling.
B. Lehmann, B. Jovanovic, Xi Chen, M. V. Estrada, Kimberly N. Johnson, Y. Shyr, H. Moses, M. Sanders, J. Pietenpol   +8 more
semanticscholar   +1 more source

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Journal of the National Cancer Institute, 2021
Background Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple ...
L. Emens, L. Molinero, S. Loi, H. Rugo, A. Schneeweiss, V. Diéras, H. Iwata, C. Barrios, M. Nechaeva, Anh Nguyen-Duc, S. Chui, A. Husain, E. Winer, S. Adams, P. Schmid   +14 more
semanticscholar   +1 more source

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)

Journal of Clinical Medicine, 2023
Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy. Although novel agents are constantly being introduced
Jieun Lee
semanticscholar   +1 more source

Radiological diagnostics of triple negative breast cancer: a review

Acta Medica Lituanica, 2011
Background. Triple negative breast cancer has a poor prognosis. Therefore, it is vital to detect this subtype of breast cancer in its early stage. The imaging features of this clinically important subtype of breast cancer are not well known.
Sigutė STADALNYKAITĖ, Rūta BRIEDIENĖ
doaj   +1 more source

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer

Cell Research, 2022
Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of metabolites in triple-negative breast cancer (TNBC) are still lacking.
Yi Xiao, D. Ma, Yun-Song Yang, Fan Yang, Jianlong Ding, Y. Gong, Linbailu Jiang, Li-Ping Ge, Songyang Wu, Qiang Z. Yu, Qing Zhang, F. Bertucci, Qiuzhuang Sun, Xin Hu, Da-Qiang Li, Z. Shao, Yizhou Jiang   +16 more
semanticscholar   +1 more source

Qualitative exploration of patients’ experiences with Intrabeam TARGeted Intraoperative radioTherapy (TARGIT-IORT) and External-Beam RadioTherapy Treatment (EBRT) for breast cancer

BMJ Open
Objective To gather a deep qualitative understanding of the perceived benefits and impacts of External-Beam RadioTherapy (EBRT) and TARGeted Intraoperative radioTherapy (TARGIT-IORT) using Intrabeam to assess how the treatments affected patient/care ...
Jayant S Vaidya, Siobhan Laws, Jennifer Royle, Sandeep Kumar Bagga, Natalie Swiderska, Charlotte Hooker, Marie Ennis-O'Connor, Siobhan Freeney, Dympna Watson, Robin Woolcock, George Lodge   +10 more
doaj   +1 more source

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021

Cancers, 2022
Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast cancers in the United States. The main treatment option remains chemotherapy, despite limited efficacy.
M. Bou Zerdan, Tala Ghorayeb, Fares Saliba, Sabine Allam, Morgan Bou Zerdan, M. Yaghi, N. Bilani, R. Jaafar, Z. Nahleh   +8 more
semanticscholar   +1 more source

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

Journal of Translational Medicine, 2023
Background Cancer/testis antigens (CTAs) participate in the regulation of malignant biological behaviors in breast cancer. However, the function and mechanism of KK-LC-1, a member of the CTA family, in breast cancer are still unclear.
Xudong Zhu, Jiawen Bu, Tong zhu, Yi Jiang   +3 more
doaj   +1 more source

Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high‐risk breast cancer

Molecular Genetics & Genomic Medicine, 2019
Background Breast cancer is the most common cancer among women worldwide. Here, we report the prevalence of BRCA1/2 mutations in patients with high‐risk breast cancer from Inner Mongolia and Jilin, China, which was a part of a nationwide project on the ...
Xiaozhen Wang, Haimeng Liu, Amina Maimaitiaili, Gang Zhao, Sijie Li, Zheng Lv, Di Wu, Aiping Shi, Xin Guan, Hongyao Jia, Menghan Li, Dong Song, Lihua Kang, Bing Han, Tong Fu, Ming Yang, Zhu Zhu, Ye Du, Yanqiu Song, Jinghui Hong, Zhimin Fan   +20 more
doaj   +1 more source